Coherus BioSciences has delivered on the first part of a plan to differentiate itself from rival pegfilgrastim biosimilars in the US by launching an autoinjector version of its existing Udenyca (pegfilgrastim-cbqv) rival to Neulasta.
Billed as Udenyca AI, the biosimilar is described by Coherus as “the only pegfilgrastim prefilled autoinjector product presentation available in...






